Project Details Successful Drug Discovery Vol. 5

Project No.:
2019-021-1-700
Start Date:
01 September 2019
End Date:
Division Name:
Chemistry and Human Health Division
Division No.:
700

Objective

The new project continues to present new drug discoveries: small-molecule-, peptide- and protein-based drugs. This will include both pioneer drugs (first in class drugs) and drug analogues (follow on drugs) in a range of therapeutic areas. The book will consist of three parts : 1. General Aspects, 2. Drug Class Studies, and 3. Case Histories of new drug discoveries described by their key inventors.

The fifth volume of “Successful Drug Discovery” will be published in 2020 by Wiley-VCH.

See Vol. 4 project

Description

For this 5th Volume, the following chapters are planned :

1. Drug Discovery in Academia
(Oliver Plettenburg, Helmholtz Zentrum, IMC Institute of Medicinal Chemistry, Munich, Germany and Wayne E. Childers, Temple University, Philadelphia, USA)
2. Small Molecules for Protein-Protein Interactions, Protein Degraders
(Bruno Martoglio, Yvonne Alice Nagel, Roche, Oncology, Basel, Switzerland)
3. CGRP Inhibitors for the Treatment of Migraine
(Sarah Walter, Antiva Biosciences and Marcelo E. Bigal, Ventus Therapeutics,USA)
4. CAR-T Therapy
(Julie Jadlowsky, Uni. of Pennsylvania, USA)
5. Oligonucleotide Therapeutics (1998-2018)
(Cy A. Stein, Dept. of Medical Oncology and Experimental Therapeutics, City of Hope Medical Center, USA)
6. GLP-1 Agonists for the Treatment of Type-2 Diabetes and Obesity
(Lars Linderoth, NovoNordisk, Denmark)
7. SGLT2 Inhibitors
(Amélia P. Rauter, University of Lisbon)
8. Discovery and Development of Emicizumab
(Tom Igawa, Chugai, Japan)
9. Discovery and Development of Ivosidenib
(Zenon D. Konteatis, Eayal Attar and Zhihua Sui, Agios Pharmaceuticals, Cambridge, USA)
10. The Discovery of Kisqali® (ribociclib), a DK4/6 Inhibitor for the Treatment of Breast Cancer
(Christopher Brain, Novartis Institute for Biomedical Research, Cambridge, MA, USA)

Progress

Page last update 11 Sep 2019